In the last trading session, 1.28 million Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares changed hands as the company’s beta touched 0.35. With the company’s per share price at $2.65 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $421.35M. MREO’s last price was a discount, traded about -89.43% off its 52-week high of $5.02. The share price had its 52-week low at $1.58, which suggests the last value was 40.38% up since then.
Analysts gave the Mereo Biopharma Group Plc ADR (MREO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MREO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Mereo Biopharma Group Plc ADR’s EPS for the current quarter is expected to be -0.01.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
However, in the 30-day time frame, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is 9.96% up.
The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 64.67% from its current market value. According to analyst projections, MREO’s forecast low is 4 with 8 as the target high. To hit the forecast high, the stock’s price needs a -201.89% plunge from its current level, while the stock would need to soar -50.94% for it to hit the projected low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
7 analysts are of the opinion that Mereo Biopharma Group Plc ADR’s revenue for the current quarter will be 7.8M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.82%. The 2025 estimates are for Mereo Biopharma Group Plc ADR earnings to increase by 57.98%, but the outlook for the next 5-year period is at 25.31% per year.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 1.6566% or 11.79 million shares worth $42.45 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were abrdn World Healthcare Fund and abrdn Life Sciences Investors. With 1.3 shares estimated at $3.45 million under it, the former controlled 0.82% of total outstanding shares. On the other hand, abrdn Life Sciences Investors held about 0.51% of the shares, roughly 812.05 shares worth around $2.15 million.
